Video

Dr. Garon Discusses the CheckMate-384 Study in NSCLC

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the CheckMate-384 study in non–small cell lung cancer.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the CheckMate-384 study in non—small cell lung cancer (NSCLC) during the 2018 European Lung Cancer Congress, which is a joint collaboration between ESMO and the IASLC.

CheckMate-384 is a phase IIIb/IV dose-frequency optimization trial in progress of nivolumab (Opdivo) in advanced or metastatic NSCLC. The currently approved dosing of nivolumab in this population is 240 mg every 2 weeks until progression or discontinuation due to toxicity. This study is investigating this regimen randomized against 480 mg every 4 weeks.

Garon says that in an ideal world, patients would not have to come into the clinic every 2 weeks for treatment. This trial is aiming to see if this higher, less frequent dosing schedule will be as effective as what is currently done in practice. Additionally, reducing dose frequency could optimize convenience during long-term nivolumab therapy, which could improve quality of life for patients.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Nicolas Girard, MD
Sally Lau, MD